Director at Abbott Laboratories (NYSE: ABT) awarded 2,286 share-linked units

Rhea-AI Filing Summary

Abbott Laboratories director Patricia Paola Gonzalez received an equity award tied to 2,286 common shares. The Form 4 shows an acquisition coded as a grant or award, with no cash price per share, reflecting stock-based compensation rather than an open-market purchase.

According to the footnote, this is a restricted stock unit award under the Abbott Laboratories 2026 Incentive Stock Program and will be paid in Abbott common shares on a one-to-one basis upon the earlier of the director’s separation from service, death, or a change in control as defined in the program. Following this award, Gonzalez directly holds 9,205 common shares.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Gonzalez Patricia Paola

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common shares without par value	2,286	$0.00	--

Holdings After Transaction: Common shares without par value — 9,205 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Equity award size: 2,286 shares Transaction price per share: $0.00 Shares held after grant: 9,205 shares

3 metrics

Equity award size 2,286 shares Restricted stock unit award linked to common shares

Transaction price per share $0.00 Grant or award acquisition, non-cash compensation

Shares held after grant 9,205 shares Direct common share holdings following the transaction

Key Terms

Restricted stock unit, Incentive Stock Program, change in control

3 terms

Restricted stock unit financial

"Restricted stock unit award granted under the Abbott Laboratories 2026 Incentive Stock Program"

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

Incentive Stock Program financial

"granted under the Abbott Laboratories 2026 Incentive Stock Program (the "Program")"

change in control financial

"death, or the occurrence of a change in control (as defined in the Program)"

A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gonzalez Patricia Paola

(Last) (First) (Middle)

100 ABBOTT PARK ROAD

(Street)

ABBOTT PARK ILLINOIS 60064

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ABBOTT LABORATORIES [ ABT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common shares without par value	04/24/2026		A		2,286(1)	A	$0	9,205	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Restricted stock unit award granted under the Abbott Laboratories 2026 Incentive Stock Program (the "Program"). The award will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

	/s/ Patricia Paola Gonzalez by Jessica H. Paik, Attorney-in-Fact	04/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Abbott Laboratories (ABT) disclose about Patricia Paola Gonzalez in this Form 4?

Abbott Laboratories reported that director Patricia Paola Gonzalez received an equity award corresponding to 2,286 common shares. The award is compensation, not a market purchase, and increased her direct holdings to 9,205 Abbott common shares after the transaction.

Is the Patricia Paola Gonzalez transaction in Abbott (ABT) stock a buy or a grant?

The transaction is a grant, not an open-market buy. The filing classifies it as a grant or award acquisition of 2,286 common-share-linked units, issued at a zero transaction price, under Abbott’s 2026 Incentive Stock Program as part of director compensation.

How many Abbott Laboratories (ABT) shares does Patricia Paola Gonzalez hold after this Form 4?

After the reported grant, Patricia Paola Gonzalez directly holds 9,205 Abbott common shares. The transaction added 2,286 share-linked units to her position, reflecting equity compensation awarded by the company’s 2026 Incentive Stock Program for directors.

What are the settlement terms of the Abbott (ABT) restricted stock unit award to Patricia Paola Gonzalez?

The restricted stock unit award will be paid in Abbott common shares on a one-to-one basis. Settlement occurs at the earlier of the director’s separation from service, death, or a change in control, as defined in Abbott Laboratories’ 2026 Incentive Stock Program.

Does Abbott Laboratories (ABT) mention a change in control condition in this director award?

Yes. The footnote explains that the restricted stock unit award pays out in Abbott common shares upon the earlier of separation from service, death, or a change in control. Change in control is specifically defined within Abbott Laboratories’ 2026 Incentive Stock Program document.